Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a medication, Clonidine can reduce the number of days a baby spends in the hospital and the number of days of medical treatment of withdrawal from Neonatal Abstinence Syndrome (NAS) as compared to Morphine Sulfate (used in routine care) .

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cooper Health System
• Treatments: Clonidine; Morphine

Criteria

Inclusion Criteria:

• Born at Cooper University Hospital

• Greater than or equal to 35 weeks gestation age

• Admitted to the NICU or Transitional nursery

• Mothers admitted to using illicit substances or prescription medications (which can result in withdrawal symptoms) while pregnant and/or had a positive urine drug screen during pregnancy.

• Babies being started on medication to control withdrawal symptoms of NAS.

• No congenital anomalies or neurologic condition (i.e. hypoxic-ischemic encephalopathy, seizures, meningitis etc.)

Exclusion Criteria:

• Premature infants <35 week gestational age

• Infants with major congenital abnormalities

• Blood pressure instability

• Major medical conditions